DE102005029845B4 - Verfahren zur Diagnose von rheumatischen Erkrankungen - Google Patents

Verfahren zur Diagnose von rheumatischen Erkrankungen Download PDF

Info

Publication number
DE102005029845B4
DE102005029845B4 DE102005029845.1A DE102005029845A DE102005029845B4 DE 102005029845 B4 DE102005029845 B4 DE 102005029845B4 DE 102005029845 A DE102005029845 A DE 102005029845A DE 102005029845 B4 DE102005029845 B4 DE 102005029845B4
Authority
DE
Germany
Prior art keywords
polypeptide
positions
residue
rheumatoid arthritis
additional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE102005029845.1A
Other languages
German (de)
English (en)
Other versions
DE102005029845A1 (de
Inventor
Dr. Bang Holger
Dr. Berg Wigbert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orgentec Diagnostika GmbH
Original Assignee
Orgentec Diagnostika GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE102005029845.1A priority Critical patent/DE102005029845B4/de
Application filed by Orgentec Diagnostika GmbH filed Critical Orgentec Diagnostika GmbH
Priority to CNA2006800312026A priority patent/CN101282989A/zh
Priority to CA2614103A priority patent/CA2614103C/en
Priority to US11/597,515 priority patent/US8999921B2/en
Priority to DE202006020682U priority patent/DE202006020682U1/de
Priority to PCT/EP2006/006205 priority patent/WO2007000320A2/de
Priority to AU2006263942A priority patent/AU2006263942B9/en
Priority to JP2008518703A priority patent/JP5174659B2/ja
Priority to EP06762214.2A priority patent/EP1896497B1/de
Publication of DE102005029845A1 publication Critical patent/DE102005029845A1/de
Priority to JP2012193246A priority patent/JP2013032358A/ja
Application granted granted Critical
Publication of DE102005029845B4 publication Critical patent/DE102005029845B4/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
DE102005029845.1A 2005-06-27 2005-06-27 Verfahren zur Diagnose von rheumatischen Erkrankungen Expired - Fee Related DE102005029845B4 (de)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DE102005029845.1A DE102005029845B4 (de) 2005-06-27 2005-06-27 Verfahren zur Diagnose von rheumatischen Erkrankungen
EP06762214.2A EP1896497B1 (de) 2005-06-27 2006-06-27 Verfahren zur diagnose von rheumatischen erkrankungen
US11/597,515 US8999921B2 (en) 2005-06-27 2006-06-27 Process for diagnosing rheumatic diseases
DE202006020682U DE202006020682U1 (de) 2005-06-27 2006-06-27 Mittel zur Diagnose von rheumatischen Erkrankungen
PCT/EP2006/006205 WO2007000320A2 (de) 2005-06-27 2006-06-27 Verfahren zur diagnose von rheumatischen erkrankungen
AU2006263942A AU2006263942B9 (en) 2005-06-27 2006-06-27 Method for diagnosing rheumatic diseases
CNA2006800312026A CN101282989A (zh) 2005-06-27 2006-06-27 用于诊断风湿性疾病的方法
CA2614103A CA2614103C (en) 2005-06-27 2006-06-27 Additional arginines in vimentin polypeptides for diagnosing rheumatic diseases
JP2008518703A JP5174659B2 (ja) 2005-06-27 2006-06-27 リウマチ疾患の診断方法
JP2012193246A JP2013032358A (ja) 2005-06-27 2012-09-03 リウマチ疾患の診断方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005029845.1A DE102005029845B4 (de) 2005-06-27 2005-06-27 Verfahren zur Diagnose von rheumatischen Erkrankungen

Publications (2)

Publication Number Publication Date
DE102005029845A1 DE102005029845A1 (de) 2007-01-11
DE102005029845B4 true DE102005029845B4 (de) 2017-03-23

Family

ID=37309237

Family Applications (2)

Application Number Title Priority Date Filing Date
DE102005029845.1A Expired - Fee Related DE102005029845B4 (de) 2005-06-27 2005-06-27 Verfahren zur Diagnose von rheumatischen Erkrankungen
DE202006020682U Expired - Lifetime DE202006020682U1 (de) 2005-06-27 2006-06-27 Mittel zur Diagnose von rheumatischen Erkrankungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE202006020682U Expired - Lifetime DE202006020682U1 (de) 2005-06-27 2006-06-27 Mittel zur Diagnose von rheumatischen Erkrankungen

Country Status (8)

Country Link
US (1) US8999921B2 (enExample)
EP (1) EP1896497B1 (enExample)
JP (2) JP5174659B2 (enExample)
CN (1) CN101282989A (enExample)
AU (1) AU2006263942B9 (enExample)
CA (1) CA2614103C (enExample)
DE (2) DE102005029845B4 (enExample)
WO (1) WO2007000320A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005029845B4 (de) 2005-06-27 2017-03-23 Orgentec Diagnostika Gmbh Verfahren zur Diagnose von rheumatischen Erkrankungen
BRPI0813262A2 (pt) * 2007-06-20 2015-04-14 Schering Corp Biomarcadores de destruição de articulação para terapia de doença inflamatória de articulação anti-il-17a
EP2204380A1 (en) 2008-12-23 2010-07-07 Charité-Universitätsmedizin Berlin hnRNP A3 related peptides and use thereof for diagnosis of rheumatoid arthritis
BRPI1013179A2 (pt) * 2009-03-30 2019-09-24 Prometheus Laboratories Inc peptídeo sintético, métodos para detectar um anticorpo de proteína anti-citrulinado em uma amostra biológica, para realizar um ensaio para ajudar no diagnóstico ou prognóstico de artrite reumatóide, para melhorar a sensibilidade de diagnosticar ou prognosticar artrite reumatóide, ensaio para diagnosticar ou prognosticar artrite reumatóide, kit, e, método para identificar um peptídeo que é imunologicamente reativo com um anticorpo de proteína anti-citrulinado
CN102229652B (zh) * 2009-10-23 2012-05-23 山东省医药生物技术研究中心 抗类风湿性关节炎的多肽及其在制药中的应用
WO2013056222A1 (en) 2011-10-14 2013-04-18 New York University Causative agents and diagnostic methods relating to rheumatoid arthritis
WO2013151314A1 (ko) * 2012-04-03 2013-10-10 연세대학교 산학협력단 비멘틴을 포함하는 탈모 억제 또는 발모 촉진용 조성물
GB201214007D0 (en) * 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
WO2016199964A1 (ko) * 2015-06-10 2016-12-15 주식회사 이뮨메드 분리된 비멘틴 유래 펩타이드에 특이적으로 결합하는 항체 또는 상기 펩타이드의 결합 단편
GB201512703D0 (en) 2015-07-20 2015-08-26 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
CN106950365B (zh) * 2017-02-15 2018-11-27 中国医学科学院北京协和医院 一种acpa阴性的ra诊断标志物及其应用
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
WO2022108309A1 (ko) * 2020-11-18 2022-05-27 한양대학교 에리카산학협력단 인산화된 비멘틴의 과도한 생성을 차단하여 암을 예방 또는 치료하는 방법
KR102511660B1 (ko) * 2020-11-18 2023-03-20 한양대학교 에리카산학협력단 비멘틴 돌연변이체 또는 이를 발현하는 벡터를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074662A2 (en) * 1999-06-07 2000-12-14 University Of Sheffield Arthritis treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9900473D0 (sv) 1999-02-12 1999-02-12 Karolinska Innovations Ab Inhibitor of endothelial cell proliferation
US9493539B2 (en) * 2003-03-07 2016-11-15 London Health Sciences Centre Research Inc. Peptides associated with HLA-DR MHC class II molecules involved in autoimmune diseases
DE102005029845B4 (de) 2005-06-27 2017-03-23 Orgentec Diagnostika Gmbh Verfahren zur Diagnose von rheumatischen Erkrankungen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074662A2 (en) * 1999-06-07 2000-12-14 University Of Sheffield Arthritis treatment

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
NELSON, R. M.; [u. a.]: A general method of site-specific mutagenesis using a modification of the Thermus aquaticus polymerase chain reaction. 1998. In: Analytical Biochemistry, Vol. 180, S. 147-151.
NELSON, R. M.; [u. a.]: A general method of site-specific mutagenesis using a modification of the Thermus aquaticus polymerase chain reaction. 1998. In: Analytical Biochemistry, Vol. 180, S. 147-151. *
PERREAU, J.; [u. a.]: Nucleotide sequence of the human vimentin gene and regulation of its transcription in tissues and cultured cells. 1988. In: Gene, Vol. 62, S. 7-16. *
VOSSENAAR, E. R.; [u. a.]: Anti-CCP antibodies, a highly specific marker for (early) rheumatoid arthritis. 2004. In: Clinical and Applied Immunology Reviews, Vol. 4, S. 239-262. Abstract
VOSSENAAR, E. R.; [u. a.]: Anti-CCP antibodies, a highly specific marker for (early) rheumatoid arthritis. 2004. In: Clinical and Applied Immunology Reviews, Vol. 4, S. 239-262. Abstract *

Also Published As

Publication number Publication date
AU2006263942B2 (en) 2012-03-29
AU2006263942A1 (en) 2007-01-04
AU2006263942B9 (en) 2012-08-02
DE102005029845A1 (de) 2007-01-11
CA2614103A1 (en) 2007-01-04
WO2007000320A2 (de) 2007-01-04
CN101282989A (zh) 2008-10-08
CA2614103C (en) 2015-02-24
US20090155822A1 (en) 2009-06-18
US8999921B2 (en) 2015-04-07
JP5174659B2 (ja) 2013-04-03
JP2008543961A (ja) 2008-12-04
EP1896497A2 (de) 2008-03-12
WO2007000320A3 (de) 2007-07-05
DE202006020682U1 (de) 2009-07-23
EP1896497B1 (de) 2017-07-12
JP2013032358A (ja) 2013-02-14

Similar Documents

Publication Publication Date Title
DE69837678T2 (de) Compositions zur inhibierung der proliferation glatter muskulatur und verfahren zur diagnose von arteriosklerose
DE69006306T2 (de) Synthetische peptide des konjugates von ubiquitin und histon h2a.
DE69431060T2 (de) Klonierte glutaminsäure-decarboxylase
DE102005029845B4 (de) Verfahren zur Diagnose von rheumatischen Erkrankungen
DE69333985T2 (de) Allergene proteine und peptide von hundhautanhangsgebilden und ihre verwendung
DE60025008T2 (de) Bestimmung von adrenomedullin-bindenden proteinen
US5776896A (en) Analgesic peptides from venom of grammostola spatulata and use thereof
DE68927635T2 (de) Igm-antikörper gegen protamin
DE3751834T2 (de) Selbstantigen der primären lebercirrhose
DE69329337T2 (de) Antibiotisches cryptdinpeptid und anwendungsmethoden
DE69836679T2 (de) Peptide zur behandlung des systemischen lupus erythematosus
DE69532714T2 (de) Verwendung von wirkstoffen zur herstellung von arzeinmitteln zur behandlung der rheumatischen arthritis
DE69629121T2 (de) Verwendung eines 24 kD Proteins zur Behandlung und Diagnose einer HCV Infektion
WO2003029824A1 (de) Verfahren und mittel zur diagnose und therapie von chronisch entzündlichen darmerkrankungen
DE69830169T2 (de) Nachweis und behandlung von krebs
DE69813620T2 (de) Verwendung von citrullin enthaltenden peptiden, die von filaggrin abstammen, zur behandlung von autoimmunkrankheiten
WO1999042480A1 (en) Analgesic peptides from venom of grammostola spatulata and use thereof
DE102014107380A1 (de) Verfahren zur Diagnose einer durch den alternativen Weg des Komplementsystems vermittelten Krankheit oder eines Risikos hierfür
WO2000040263A1 (de) Herstellung und verwendung einer zusammensetzung mit ivig zur behandlung von erkrankungen mit erhöhten extrazellulären fasl-titern
EP1171464A2 (de) Von interleukin 12 abgeleitete peptid-homodimere und peptid-heterodimere
HK1124345A (en) Method for diagnosing rheumatic diseases
EP1171463A2 (de) Von interferon alpha 2 abgeleitete peptid-homodimere und peptid-heterodimere
WO1998032772A1 (de) POLYKLONALER ANTIKÖRPER ZUM NACHWEIS DES TUMORASSOZIIERTEN ANTIGENS hTid
WO2007028592A1 (de) Beeinflussung des kardialen fc-rezeptors zur behandlung der dilatativen kardiomyopathie

Legal Events

Date Code Title Description
R012 Request for examination validly filed

Effective date: 20120313

R016 Response to examination communication
R018 Grant decision by examination section/examining division
R020 Patent grant now final
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee